Engineering Human Stem Cell-Derived Islets to Evade Immune Rejection and Promote Localized Immune Tolerance

Scientists demonstrated that targeting human leukocyte antigens and PD-L1 alone did not sufficiently protect stem cell-derived islet cells from xenograft- or allograft-rejection.